Prospective Cohort Study of Palbociclib Treatment in Postmenopausal Patients With Unresectable and Metastatic Hormone Receptor-Positive Breast Cancer: Study Protocol for a CSPOR-BC Palbociclib Cohort Trial

BACKGROUND: Combining palbociclib with letrozole or fulvestrant improved progression-free survival in hormone receptor (HR)-positive and human epidermal growth factor receptor-negative metastatic breast cancer. However, combining palbociclib to endocrine treatment increases toxicity and cost compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Narui, Kazutaka, Ishikawa, Takashi, Taira, Naruto, Uemura, Yukari, Mukai, Hirofumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451568/
https://www.ncbi.nlm.nih.gov/pubmed/36128589
http://dx.doi.org/10.14740/wjon1507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451568/
https://www.ncbi.nlm.nih.gov/pubmed/36128589
http://dx.doi.org/10.14740/wjon1507

Ejemplares similares